Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy

Erica C. Bruce, Ying Guo, Kathryn C. Lawson, Amita K. Manatunga, S. Freda Auyeung, William M. McDonald, Natasha Rushing, Angelo R. Brown, Natalie Gilles, Milburn Emery, Robert Bonsall, Jocelyn Porquez, Zachary Stowe, Charles B. Nemeroff, Dominique L. Musselman

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


OBJECTIVE: To determine a) whether clinical response to electroconvulsive therapy (ECT) is associated with decreased platelet activation in patients with major depressive disorder (MDD) and b) if any medical/demographic characteristics predict response to ECT or changes in platelet activation. Increased platelet activation may underlie the increased risk of coronary artery disease (CAD) in patients with MDD. METHODS: Before their first and sixth ECT treatments, study patients (n = 44) completed the Beck Depression Inventory (BDI) to assess the severity of depressive symptoms. Activity of the platelet thromboxane (TBX) A2 pathway was assessed by measuring the morning spot urinary concentrations of 11-dehydroxy-thromboxane B2 (11-D-TBX B2), a major metabolite of platelet-derived TBX A2. RESULTS: Multivariate logistic regression analyses revealed that improvement on the BDI was significantly more likely in patients without a history of hypertension (p = .02) and in patients who were prescribed a greater number of "platelet-altering" medications (p = .03). During a course of ECT, a decrease in urinary 11-D-TBX B2 was significantly more likely to occur in ECT nonresponders (p = .01) and younger patients (p = .02). CONCLUSIONS: Clinical response to ECT coadministered may not be associated with decreases in platelet-derived TBX. Future studies will confirm which somatic "antidepression" treatments offer optimal thrombovascular benefits for depressed patients with multiple risk factors for, or clinically evident, cerebral disease or CAD.

Original languageEnglish (US)
Pages (from-to)319-327
Number of pages9
JournalPsychosomatic medicine
Issue number3
StatePublished - Apr 2008
Externally publishedYes


  • Antidepressants
  • Autocrine pathways
  • Electroconvulsive therapy
  • Major depressive disorder
  • Platelet function
  • Thromboxane

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)


Dive into the research topics of 'Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy'. Together they form a unique fingerprint.

Cite this